



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Sifalimumab

Cat. No.:	HY-P99219
CAS No.:	1006877-41-3
Target:	IFNAR
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Sifalimumab (MEDI-545) is an anti-IFN $\alpha$ monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFN $\alpha$ ) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research <sup>[1][2]</sup> .									
<b>In Vitro</b>	<p>Sifalimumab (3-36 <math>\mu</math>g/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>U-87MG cells and AGS lymphocytes</td> </tr> <tr> <td>Concentration:</td> <td>3-36 <math>\mu</math>g/well</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Attenuated lymphocyte cytotoxicity triggered by IFN I (P&lt;0.05).</td> </tr> </table>		Cell Line:	U-87MG cells and AGS lymphocytes	Concentration:	3-36 $\mu$ g/well	Incubation Time:	72 hours	Result:	Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).
Cell Line:	U-87MG cells and AGS lymphocytes									
Concentration:	3-36 $\mu$ g/well									
Incubation Time:	72 hours									
Result:	Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).									
<b>In Vivo</b>	<p>Sifalimumab (subcutaneous injection; 30 mg/kg and 3 <math>\mu</math>g/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Wild-type male BALB/c mice<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg and 3 <math>\mu</math>g/g</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection; 30 mg/kg and 3 <math>\mu</math>g/g</td> </tr> <tr> <td>Result:</td> <td>Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P &lt; 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P&lt;0.05).</td> </tr> </table>		Animal Model:	Wild-type male BALB/c mice <sup>[2]</sup>	Dosage:	30 mg/kg and 3 $\mu$ g/g	Administration:	Subcutaneous injection; 30 mg/kg and 3 $\mu$ g/g	Result:	Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05).
Animal Model:	Wild-type male BALB/c mice <sup>[2]</sup>									
Dosage:	30 mg/kg and 3 $\mu$ g/g									
Administration:	Subcutaneous injection; 30 mg/kg and 3 $\mu$ g/g									
Result:	Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05).									

---

## REFERENCES

---

[1]. Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon  $\alpha$  monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. *Ann Rheum Dis*. 2011 Nov;70(11):1905-13.

[2]. La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. *Drug Deliv Transl Res*. 2018 Oct;8(5):1345-1354.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA